A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis.

We have shown previously that AWT1 and WT1-AS are functionally imprinted in human kidney. In the adult kidney, expression of both transcripts is restricted to the paternal allele, with the silent maternal allele retaining methylation at the WT1 antisense regulatory region (WT1 ARR). Here, we report characterization of the WT1 ARR differentially methylated region and show that it contains a transcriptional silencer element acting on both the AWT1 and WT1-AS promoters. DNA methylation of the silencer results in increased transcriptional repression, and the silencer is also shown to be an in vitro and in vivo target site for the imprinting regulator protein CTCF. Binding of CTCF is methylation-sensitive and limited to the unmethylated silencer. Potentiation of the silencer activity is demonstrated after CTCF protein is knocked down, suggesting a novel silencer-blocking activity for CTCF. We also report assessment of WT1 ARR methylation in developmental and tumour tissues, including the first analysis of Wilms' tumour precursor lesions, nephrogenic rests. Nephrogenic rests show increases in methylation levels relative to foetal kidney and reductions relative to the adult kidney, together with biallelic expression of AWT1 and WT1-AS. Notably, the methylation status of CpG residues within the CTCF target site appears to distinguish monoallelic and biallelic expression states. Our data suggest that failure of methylation spreading at the WT1 ARR early in renal development, followed by imprint erasure, occurs during Wilms' tumourigenesis. We propose a model wherein imprinting defects at chromosome 11p13 may contribute to Wilms' tumourigenesis.

[1]  Peter Hohenstein,et al.  The many facets of the Wilms' tumour gene, WT1. , 2006, Human molecular genetics.

[2]  Anwar Hossain,et al.  N-terminally Truncated WT1 Protein with Oncogenic Properties Overexpressed in Leukemia* , 2006, Journal of Biological Chemistry.

[3]  Rolf Ohlsson,et al.  CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Allen R. Chen,et al.  The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. , 2006, Blood.

[5]  Y. Tsunematsu,et al.  Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin‐like growth factor–II in Wilms tumor , 2006, Genes, chromosomes & cancer.

[6]  F. Recillas-Targa,et al.  A CTCF-Dependent Silencer Located in the Differentially Methylated Area May Regulate Expression of a Housekeeping Gene Overlapping a Tissue-Specific Gene Domain , 2006, Molecular and Cellular Biology.

[7]  R. Myers,et al.  Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome. , 2005, Genome research.

[8]  W. Reik,et al.  Molecular subtypes and phenotypic expression of Beckwith–Wiedemann syndrome , 2005, European Journal of Human Genetics.

[9]  Victor V Lobanenkov,et al.  Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. , 2005, Cancer research.

[10]  B. Tycko,et al.  Genomic Profiling Maps Loss of Heterozygosity and Defines the Timing and Stage Dependence of Epigenetic and Genetic Events in Wilms' Tumors , 2005, Molecular Cancer Research.

[11]  Victor V Lobanenkov,et al.  Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. , 2005, Cancer research.

[12]  A. Feinberg,et al.  Association of chromosome arm 16q loss with loss of imprinting of insulin‐like growth factor–II in Wilms tumor , 2005, Genes, chromosomes & cancer.

[13]  T. Bestor,et al.  Identification of the control region for tissue-specific imprinting of the stimulatory G protein alpha-subunit. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Rolf Ohlsson,et al.  Poly(ADP-ribosyl)ation regulates CTCF-dependent chromatin insulation , 2004, Nature Genetics.

[15]  A. C. Williams,et al.  Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. , 2003, Human molecular genetics.

[16]  R. Weksberg,et al.  Insulator and silencer sequences in the imprinted region of human chromosome 11p15.5. , 2003, Human molecular genetics.

[17]  K. Wagner,et al.  The complex life of WT1 , 2003, Journal of Cell Science.

[18]  B. Tycko,et al.  Chromosome arm 16q in Wilms tumors: Unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene , 2002, Genes, chromosomes & cancer.

[19]  Victor V Lobanenkov,et al.  The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. , 2002, Seminars in cancer biology.

[20]  J. J. Breen,et al.  BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R Ohlsson,et al.  CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. , 2001, Trends in genetics : TIG.

[22]  A. Jochemsen,et al.  WT1 proteins: functions in growth and differentiation. , 2001, Gene.

[23]  A. Feinberg,et al.  Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. , 2001, Cancer research.

[24]  K. Malik,et al.  Epigenetic gene deregulation in cancer , 2000, British Journal of Cancer.

[25]  Victor V Lobanenkov,et al.  Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive , 2000, Current Biology.

[26]  K. Moorwood,et al.  Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor. , 2000, Cancer research.

[27]  P. Neiman,et al.  Negative Transcriptional Regulation Mediated by Thyroid Hormone Response Element 144 Requires Binding of the Multivalent Factor CTCF to a Novel Target DNA Sequence* , 1999, The Journal of Biological Chemistry.

[28]  C. Y. Wang,et al.  WT1 modulates apoptosis by transcriptionally upregulating the bcl‐2 proto‐oncogene , 1999, The EMBO journal.

[29]  J. Beckwith,et al.  Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. , 1998, American journal of medical genetics.

[30]  A. Charles,et al.  Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development. , 1998, The American journal of pathology.

[31]  K. Moorwood,et al.  Antisense WT1 transcription parallels sense mRNA and protein expression in fetal kidney and can elevate protein levels in vitro , 1998, The Journal of pathology.

[32]  K. Pritchard-Jones,et al.  Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. , 1998, Blood.

[33]  S. Ogbourne,et al.  Transcriptional control and the role of silencers in transcriptional regulation in eukaryotes. , 1998, The Biochemical journal.

[34]  A. Reeve,et al.  Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Victor V Lobanenkov,et al.  Negative protein 1, which is required for function of the chicken lysozyme gene silencer in conjunction with hormone receptors, is identical to the multivalent zinc finger repressor CTCF , 1997, Molecular and cellular biology.

[36]  P. Neiman,et al.  An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes , 1996, Molecular and cellular biology.

[37]  A. Jochemsen,et al.  Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells. , 1996, Oncogene.

[38]  K. Malik,et al.  Identification of an antisense WT1 promoter in intron 1: implications for WT1 gene regulation. , 1995, Oncogene.

[39]  B. Williams,et al.  Wilms Tumor: Clinical and Molecular Characterization , 1995, Molecular Biology Intelligence Unit.

[40]  M. Eccles,et al.  Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour. , 1995, Oncogene.

[41]  K. Malik,et al.  Autoregulation of the human WT1 gene promoter , 1994, FEBS letters.

[42]  Osamu Ogawa,et al.  Cloning of novel Wilms tumor gene (WT1) cDNAs; evidence for antisense transcription of WT1. , 1994, Oncogene.

[43]  N. Niikawa,et al.  Mosaic and polymorphic imprinting of the WT1 gene in humans , 1994, Nature Genetics.

[44]  David Housman,et al.  WT-1 is required for early kidney development , 1993, Cell.

[45]  J. Cowell,et al.  Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene. , 1993, British Journal of Cancer.

[46]  L. Breeden,et al.  Characterization of a “silencer” in yeast: A DNA sequence with properties opposite to those of a transcriptional enhancer , 1985, Cell.

[47]  S. Tilghman,et al.  CTCF maintains differential methylation at the Igf2/H19 locus , 2003, Nature Genetics.

[48]  A. Feinberg,et al.  Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. , 2002, Cancer research.

[49]  M. Little,et al.  A clinical overview of WT1 gene mutations , 1997, Human mutation.

[50]  B. Williams,et al.  Antisense transcripts and protein binding motifs within the Wilms tumour (WT1) locus. , 1994, Oncogene.